On January 4, 2021, David Marek joined Myovant Sciences Ltd. as Principal Executive Officer and a member of the Board of Directors and also as Chief Executive Officer of its subsidiary, Myovant Sciences Inc. Mr.Marek served as Chief Commercial Officer of Axsome Therapeutics, where he led the buildout of commercial capabilities in preparation for anticipated product launches, from September 2019 to December 2020. Prior to joining Axsome, from June 2017 to August 2019, Mr. Marek held the position of Vice President, and General Manager of Amgen's Neuroscience business unit. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig for migraine prevention. Prior to heading the Neuroscience business unit, he was Vice President of Marketing of Amgen's U.S. Inflammation and Nephrology business from June 2015 to June 2017.